Showing 91-100 of 3130 results for "".
What Will Be Our Legacy?
https://practicaldermatology.com/topics/practice-management/what-will-be-our-legacy/21434/Practical Dermatology® Magazine Welcomes Neal Bhatia, MD, FAAD as Co-Chief Medical EditorCSF 2016 Highlights from the Founder
https://practicaldermatology.com/topics/skin-cancer-photoprotection/csf-2016-highlights-from-the-founder/18711/Cosmetic Surgery Forum Founder and Practical Dermatology® Chief Surgical Editor Joel Schlessinger, MD talks about CSF 2016. What sets the meeting apart? How has it evolved in 8 years? And what did he learn from this year's program? Find out.Make Your Mark: Formulate a Product Line
https://practicaldermatology.com/topics/practice-management/make-your-mark-formulate-a-product-line/20023/Dispensing skincare offers benefits to your practice and your patients. Joel Schlessinger, MD discusses his journey with his son to developing their own product formulation and offers insights and encourages colleagues to use their unique talents to do the same.CSF 2022 Highlights
https://practicaldermatology.com/conferences/cosmetic-surgery-forum-2022/csf-2022-highlights/20162/Joel Schlessinger, MD says the 2022 Cosmetic Surgery Forum was a success. The unique format of the meeting encourages presenters and audience members to interact and engage in lively discussions that allow attendees to leave the meeting with ideas they can use in their practices immediately.Topical Toxins: Now and Later
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/topical-toxins-now-and-later/18768/Topical neurotoxins are in late-stage development, with the potential to offer "softer" results and reduction of fine wrinkles. But they may not be approved for another few years. In the meantime, micro channel delivery of toxins, such as with AquaGold, is an option. Joel Schlessinger, MD, founder oPearls from CSF 2022
https://practicaldermatology.com/conferences/cosmetic-surgery-forum-2022/pearls-from-csf-2022/20163/It’s not just the attendees who learned at this year’s Cosmetic Surgery Forum. Meeting founder Joel Schlessinger, MD discusses some of the presentations that were most impactful to him. From presentations about the effectiveness of new technology to discussions about the usefulness of hyaluronidaseScientifically Speaking: Effective By Design with Josh Makower, MD
https://practicaldermatology.com/series/scientifically-speaking/scientifically-speaking-effective-by-design-with-josh-makower-md/20106/Josh Makower, MD has been at the forefront of several medical innovations. Listen in as he describes his approach and discusses his latest product with host Joel L. Cohen, MD. The Avéli device from Revelle Aesthetics is FDA-cleared to reduce cellulite in the buttocks and thighs temporarily.Journal Club: Combination Therapy With Dupilumab and Upadacitinib
https://practicaldermatology.com/programs/Practical-Dermatology-Atopic-Dermatitis-Journal-Club/journal-club-combination-therapy-with-dupilumab-and-upadacitinib/32408/Neal Bhatia, MD, FAAD, and Ted Lain, MD, MBA, FAAD, discuss the International Journal of Dermatology article “Combination Therapy With Upadacitinib and Dupilumab for Severe Atopic Dermatitis,” and their own experiences with similar treatment strategies.Practical Dermatology Roundtable: Generalized Pustular Psoriasis, Ch. 1
https://practicaldermatology.com/series/the-practical-dermatology-roundtable/practical-dermatology-roundtable-generalized-pustular-psoriasis-ch-1/32757/In the first installment of a six-part series, host Neal Bhatia, MD, FAAD, and guests Jason E. Hawkes, MD, MS, FAAD, and Laura K. Ferris, MD, PhD, FAAD, provide an overview of generalized pustular psoriasis, including the unique challenges it poses, triggers associated with it, and the importance ofPractical Dermatology Roundtable: Generalized Pustular Psoriasis, Ch. 5
https://reachmd.com/programs/the-practical-dermatology-roundtable/practical-dermatology-roundtable-generalized-pustular-psoriasis-ch-5/32903/Host Neal Bhatia, MD, FAAD, and guests Jason E. Hawkes, MD, MS, FAAD, and Laura K. Ferris, MD, PhD, FAAD, discuss getting clinicians out of the mindset of using traditional IL-17 and IL-23 blockers for generalized pustular psoriasis, understanding that it is a chronic disease that needs a chronic tr